content: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): January 1, 2007
                                                            ---------------
  
                                 CYTOGEN CORPORATION
                  ------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
           Delaware                      000-14879                  22-2322400
  ----------------------------     ------------------------    -------------------
  (State or Other Jurisdiction   (Commission File Number)       (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  ---------------------------------------------------------    -------------------
          (Address of Principal Executive Offices)                  (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  
  
  <PAGE>
  
  
  Item 5.02  Departure of Directors or Principal Officers;  Election of Directors;
             Appointment  of Principal  Officers;   Compensatory  Arrangements  of
             Certain Officers.
  
       In connection with its annual performance review process,  the Compensation
  Committee  and the Board of Directors  of Cytogen  Corporation  (the  "Company")
  approved,  as of January 1, 2007, the annual  incentive (i.e. cash bonus) awards
  for the period January 1, 2006 to December 31, 2006 and the annual  salaries for
  2007 for executive officers of the  Company.
  
       The annual incentive awards, as shown in the table below, were based on the
  Compensation  Committee's  assessment  of the  Company's  and  each  executive's
  performance measured against previously set financial and strategic objectives.
  
       The following table sets forth the cash bonus amounts for 2006  performance
  and the annual base  salaries for 2007 for the  executive  officers  (Michael D.
  Becker, Kevin J. Bratton,  William F. Goeckeler, and William J. Thomas) who will
  be  included  as the  Named  Executive  Officers  in the  Company's  2007  proxy
  statement.
  
  
  --------------------------------------------------------------------------------
  NAME                   TITLE                        2006 BONUS      2007 SALARY
  --------------------------------------------------------------------------------
  
  --------------------------------------------------------------------------------
  Michael D. Becker      President and Chief          $160,808        $383,720
                          Executive Officer
  --------------------------------------------------------------------------------
  Kevin J. Bratton       Senior Vice President,       $ 20,000        $225,000
                          Finance, and Chief
                          Financial Officer
  --------------------------------------------------------------------------------
  William F. Goeckeler   Senior Vice President,       $ 91,664        $277,156
                          Operations
  --------------------------------------------------------------------------------
  William J. Thomas      Senior Vice President and    $ 66,338        $253,386
                          General Counsel
  --------------------------------------------------------------------------------
  
       The  Named  Executive   Officers  do  not  currently  have  any  employment
  agreements with the Company.
  
                                     SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                   CYTOGEN CORPORATION
  
  
  
                                                   By: /s/ William J. Thomas
                                                      ----------------------------
                                                      William J. Thomas
                                                      Senior Vice President and
                                                        General Counsel
  
  Dated: January 4, 2007
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "form8k_010407.txt", "description": "FORM 8-K COMPENSATION 010407", "secsgml_size_bytes": 5384}]
metadata_filer: {"company-data": {"conformed-name": "CYTOGEN CORP", "cik": "0000725058", "assigned-sic": "2834", "irs-number": "222322400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-14879", "film-number": "07510218"}, "business-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540", "phone": "6099878200"}, "mail-address": {"street1": "650 COLLEGE RD EAST STE 3100", "city": "PRINCETON", "state": "NJ", "zip": "08540"}}
text: UNITED STATES
  
                         SECURITIES AND EXCHANGE COMMISSION
  
                               WASHINGTON, D.C. 20549
  
                      ----------------------------------------
  
                                      FORM 8-K
  
                                   CURRENT REPORT
  
                       PURSUANT TO SECTION 13 OR 15(d) OF THE
                           SECURITIES EXCHANGE ACT OF 1934
  
          Date of report (Date of earliest event reported): January 1, 2007
                                                            ---------------
  
                                 CYTOGEN CORPORATION
                  ------------------------------------------------
                 (Exact Name of Registrant as Specified in Charter)
  
           Delaware                      000-14879                  22-2322400
  ----------------------------     ------------------------    -------------------
  (State or Other Jurisdiction   (Commission File Number)       (I.R.S. Employer
       of Incorporation)                                       Identification No.)
  
  650 College Road East, CN 5308, Suite 3100, Princeton, NJ           08540
  ---------------------------------------------------------    -------------------
          (Address of Principal Executive Offices)                  (Zip Code)
  
         Registrant's telephone number, including area code: (609) 750-8200
                                                             --------------
  
  --------------------------------------------------------------------------------
            (Former Name or Former Address, if Changed Since Last Report)
  
       Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
  simultaneously  satisfy the filing obligation of the registrant under any of the
  following provisions (see General Instruction A.2. below):
  
       |_|  Written communications  pursuant to Rule 425 under the  Securities Act
  (17 CFR 230.425)
  
       |_|  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
  CFR 240.14a-12)
  
       |_|  Pre-commencement  communications  pursuant to Rule 14d-2(b)  under the
  Exchange Act (17 CFR 240.14d-2(b))
  
       |_|  Pre-commencement  communications  pursuant to Rule 13e-4(c)  under the
  Exchange Act (17 CFR 240.13e-4(c))
  Item 5.02  Departure of Directors or Principal Officers;  Election of Directors;
             Appointment  of Principal  Officers;   Compensatory  Arrangements  of
             Certain Officers.
  
       In connection with its annual performance review process,  the Compensation
  Committee  and the Board of Directors  of Cytogen  Corporation  (the  "Company")
  approved,  as of January 1, 2007, the annual  incentive (i.e. cash bonus) awards
  for the period January 1, 2006 to December 31, 2006 and the annual  salaries for
  2007 for executive officers of the  Company.
  
       The annual incentive awards, as shown in the table below, were based on the
  Compensation  Committee's  assessment  of the  Company's  and  each  executive's
  performance measured against previously set financial and strategic objectives.
  
       The following table sets forth the cash bonus amounts for 2006  performance
  and the annual base  salaries for 2007 for the  executive  officers  (Michael D.
  Becker, Kevin J. Bratton,  William F. Goeckeler, and William J. Thomas) who will
  be  included  as the  Named  Executive  Officers  in the  Company's  2007  proxy
  statement.
  
  --------------------------------------------------------------------------------
  NAME                   TITLE                        2006 BONUS      2007 SALARY
  --------------------------------------------------------------------------------
  
  --------------------------------------------------------------------------------
  Michael D. Becker      President and Chief          $160,808        $383,720
                          Executive Officer
  --------------------------------------------------------------------------------
  Kevin J. Bratton       Senior Vice President,       $ 20,000        $225,000
                          Finance, and Chief
                          Financial Officer
  --------------------------------------------------------------------------------
  William F. Goeckeler   Senior Vice President,       $ 91,664        $277,156
                          Operations
  --------------------------------------------------------------------------------
  William J. Thomas      Senior Vice President and    $ 66,338        $253,386
                          General Counsel
  --------------------------------------------------------------------------------
  
       The  Named  Executive   Officers  do  not  currently  have  any  employment
  agreements with the Company.
  
                                     SIGNATURES
  
       Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
  Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
  undersigned hereunto duly authorized.
  
                                                   CYTOGEN CORPORATION
  
                                                   By: /s/ William J. Thomas
                                                      ----------------------------
                                                      William J. Thomas
                                                      Senior Vice President and
                                                        General Counsel
  
  Dated: January 4, 2007